Literature DB >> 9283786

Excess costs of medical care for patients with diabetes in a managed care population.

J V Selby1, G T Ray, D Zhang, C J Colby.   

Abstract

OBJECTIVE: To estimate the excess costs of medical care for patients with diabetes in a managed care population and to determine the proportion of costs spent on treating the complications of diabetes. RESEARCH DESIGN AND METHODS: A comparison of 1-year (1994) costs of medical care in the 85,209 members of the diabetes registry of Kaiser Permanente, Northern California, and in 85,209 age- and sex-matched nondiabetic control subjects. Costs were obtained from automated program databases. Costs specifically related to treating acute and long-term complications of diabetes were identified, and the excess costs attributable to each complication in individuals with diabetes were calculated.
RESULTS: Excess expenditures in individuals with diabetes totaled $282.7 million, or $3,494 per person. Per person expenditures for members with diabetes were 2.4 times those for matched control subjects. The largest proportion of total excess costs was for hospitalizations within the health maintenance organization (38.5%). Nearly 38% of the total excess was spent treating the long-term complications of diabetes, predominantly coronary heart disease and end-stage renal disease.
CONCLUSIONS: Diabetes is a costly condition by virtue of its high prevalence and high per person costs. A large proportion of these costs are related to treating complications of diabetes. Available evidence indicates that several measures can reduce complication rates. Thus, effective disease management programs that aim to prevent complications could potentially lead to cost savings in managed care settings.

Entities:  

Mesh:

Year:  1997        PMID: 9283786     DOI: 10.2337/diacare.20.9.1396

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  96 in total

1.  The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study.

Authors:  I Köster; L von Ferber; P Ihle; I Schubert; H Hauner
Journal:  Diabetologia       Date:  2006-05-11       Impact factor: 10.122

2.  Timing of hormone therapy and dementia: the critical window theory revisited.

Authors:  Rachel A Whitmer; Charles P Quesenberry; Jufen Zhou; Kristine Yaffe
Journal:  Ann Neurol       Date:  2010-11-12       Impact factor: 10.422

3.  Type 2 diabetes mellitus and its complications: from the molecular biology to the clinical practice.

Authors:  Maciej T Malecki
Journal:  Rev Diabet Stud       Date:  2004-05-10

4.  Metformin use and lung cancer risk in patients with diabetes.

Authors:  Lori C Sakoda; Assiamira Ferrara; Ninah S Achacoso; Tiffany Peng; Samantha F Ehrlich; Charles P Quesenberry; Laurel A Habel
Journal:  Cancer Prev Res (Phila)       Date:  2015-02

5.  Characteristics of insured patients with persistent gaps in diabetes care services: the Translating Research into Action for Diabetes (TRIAD) study.

Authors:  Edward W Gregg; Andrew J Karter; Robert B Gerzoff; Monika Safford; Arleen F Brown; Chien-Wen Tseng; Beth Waitzfielder; William H Herman; Carol M Mangione; Joseph V Selby; Theodore J Thompson; R Adams Dudley
Journal:  Med Care       Date:  2010-01       Impact factor: 2.983

6.  Trends in Incidence of Hospitalized Acute Myocardial Infarction in the Cardiovascular Research Network (CVRN).

Authors:  Kristi Reynolds; Alan S Go; Thomas K Leong; Denise M Boudreau; Andrea E Cassidy-Bushrow; Stephen P Fortmann; Robert J Goldberg; Jerry H Gurwitz; David J Magid; Karen L Margolis; Catherine J McNeal; Katherine M Newton; Rachel Novotny; Charles P Quesenberry; Wayne D Rosamond; David H Smith; Jeffrey J VanWormer; Suma Vupputuri; Stephen C Waring; Marc S Williams; Stephen Sidney
Journal:  Am J Med       Date:  2016-10-14       Impact factor: 4.965

7.  Trends and racial and ethnic disparities in the prevalence of pregestational type 1 and type 2 diabetes in Northern California: 1996-2014.

Authors:  Tiffany Y Peng; Samantha F Ehrlich; Yvonne Crites; John L Kitzmiller; Michael W Kuzniewicz; Monique M Hedderson; Assiamira Ferrara
Journal:  Am J Obstet Gynecol       Date:  2016-10-15       Impact factor: 8.661

8.  Incidence, prevalence and coronary heart disease risk level in known Type 2 diabetes: a sentinel practice network study in the Basque Country, Spain.

Authors:  J M Arteagoitia; M I Larrañaga; J L Rodriguez; I Fernandez; J A Piniés
Journal:  Diabetologia       Date:  2003-06-27       Impact factor: 10.122

9.  Examining the economic costs related to lifestyle and pharmacological interventions in youth with Type 2 diabetes.

Authors:  Thomas Songer; Judith Glazner; Laura P Coombs; Leona Cuttler; Mary Daniel; Silvia Estrada; Georgeanna Klingensmith; Andrea Kriska; Lori Laffel; Ping Zhang
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2006-06-01       Impact factor: 2.217

10.  The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study.

Authors:  Elbert S Huang; Andrew J Karter; Kirstie K Danielson; E Margaret Warton; Ameena T Ahmed
Journal:  J Gen Intern Med       Date:  2009-12-05       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.